{"id":539740,"date":"2021-04-21T18:56:02","date_gmt":"2021-04-21T18:56:02","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=539740"},"modified":"2021-04-21T18:56:02","modified_gmt":"2021-04-21T18:56:02","slug":"glioblastoma-multiforme-market-industry-trends-drugs-therapies-and-analysis-by-delveinsight-genentech-merck-vbl-therapeutics-diffusion-pharmaceuticals-bayer-medimmune-dnatrix-oncoceutics","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/glioblastoma-multiforme-market-industry-trends-drugs-therapies-and-analysis-by-delveinsight-genentech-merck-vbl-therapeutics-diffusion-pharmaceuticals-bayer-medimmune-dnatrix-oncoceutics_539740.html","title":{"rendered":"Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics"},"content":{"rendered":"<div style=\"float:right; width:250px; padding:8px 10px 10px 10px;\"><a href=\"https:\/\/www.abnewswire.com\/uploads\/1618993395.jpeg\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img loading=\"lazy\" decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics\" src=\"https:\/\/www.abnewswire.com\/uploads\/1618993395.jpeg\" alt=\"Glioblastoma Multiforme Market: Industry trends, Drugs, Therapies and Analysis by DelveInsight |Genentech, Merck, VBL Therapeutics, Diffusion Pharmaceuticals, Bayer, MedImmune, DNAtrix, Oncoceutics\" width=\"225\" height=\"225\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\">\n<div>Glioblastoma Multiforme Market<\/div>\n<\/div>\n<\/div>\n<p style=\"text-align: justify;\"><strong>Glioblastoma<\/strong> is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.<\/p>\n<p style=\"text-align: justify;\">DelveInsight&rsquo;s<strong>&nbsp;&lsquo;<strong><a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Glioblastoma Multiforme Market<\/a>&nbsp;<\/strong>Insights, Epidemiology and Market Forecast&ndash; 2030&rsquo;<\/strong>&nbsp;report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.<\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Key Findings of Glioblastoma Multiforme Market Report:<\/strong><\/p>\n<p style=\"text-align: justify;\">This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.<\/p>\n<ul style=\"text-align: justify;\">\n<li>The market size of GBM in the seven major markets was estimated to be&nbsp;<strong>USD 1,005 Million<\/strong>&nbsp;in 2017.<\/li>\n<li>The United States accounts for the largest market size of GBM throughout the study period of 2017&ndash;2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be&nbsp;<strong>USD 629 Million<\/strong>&nbsp;in 2017.<\/li>\n<li>Among the EU5 countries, Germany had the highest market size with&nbsp;<strong>USD 73 Million<\/strong>&nbsp;in 2017, while Spain had the lowest market size with&nbsp;<strong>USD 35 Million.<\/strong><\/li>\n<li>Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020&ndash;2030, which was estimated to be&nbsp;<strong>USD 82 Million&nbsp;<\/strong>in 2017.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Scope of the Glioblastoma Multiforme Report :<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>The report covers the descriptive overview of Glioblastoma Multiforme (GBM), explaining its causes, signs and symptoms, pathogenesis and currently available therapies.<\/li>\n<li>Comprehensive insight has been provided into the Glioblastoma Multiforme (GBM) epidemiology and treatment.<\/li>\n<li>Additionally, an all-inclusive account of both the current and emerging therapies for Glioblastoma Multiforme (GBM) are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape.<\/li>\n<li>A detailed review of Glioblastoma Multiforme (GBM) market; historical and forecasted is included in the report, covering the 7MM drug outreach.<\/li>\n<li>The report provides an edge while developing business strategies, by understanding trends shaping and driving the 7MM Glioblastoma Multiforme (GBM) market.<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><img decoding=\"async\" style=\"display: block; margin-left: auto; margin-right: auto;\" src=\"https:\/\/www.abnewswire.com\/uploads\/aa7fda668ccfa2fc00e49bfb1a6f3526.jpg\" alt=\"\" \/><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report:&nbsp;<a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of Glioblastoma Multiforme Companies are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Genentech&nbsp;&nbsp;<\/li>\n<li>Merck&nbsp;&nbsp;<\/li>\n<li>VBL Therapeutics&nbsp;&nbsp;<\/li>\n<li>Diffusion Pharmaceuticals&nbsp;&nbsp;<\/li>\n<li>Bayer&nbsp;&nbsp;<\/li>\n<li>MedImmune&nbsp;&nbsp;<\/li>\n<li>DNAtrix&nbsp;&nbsp;<\/li>\n<li>Oncoceutics&nbsp;&nbsp;<\/li>\n<li>Karyopharm Therapeutics&nbsp;&nbsp;<\/li>\n<li>Kazia Therapeutics&nbsp;&nbsp;<\/li>\n<li>Aivita Biomedical&nbsp;&nbsp;<\/li>\n<li>Medicenna Therapeutics<\/li>\n<li>And Many others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Some of <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">Glioblastoma Multiforme Therapies<\/a> are:<\/strong><\/p>\n<ul style=\"text-align: justify;\">\n<li>Avastin<\/li>\n<li>Temodar\/Temodal<\/li>\n<li>Ofranergene obadenovec (VB-111)<\/li>\n<li>Trans Sodium Crocetinate<\/li>\n<li>Regorafenib<\/li>\n<li>Durvalumab (MEDI4736)<\/li>\n<li>Tasadenoturev (DNX-2401)<\/li>\n<li>ONC201<\/li>\n<li>Selinexor (KPT-330)<\/li>\n<li>Paxalisib (GDC-0084)<\/li>\n<li>AV-GBM-1<\/li>\n<li>MDNA55<\/li>\n<li>And Many Others<\/li>\n<\/ul>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Free Sample Report: <a rel=\"nofollow\" href=\"https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market?utm_source=SatPR&amp;utm_medium=pressrelease&amp;utm_campaign=apr\">https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/a><\/strong><\/p>\n<p style=\"text-align: justify;\">&nbsp;<\/p>\n<p style=\"text-align: justify;\"><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\">1 Key Insights<\/p>\n<p style=\"text-align: justify;\">2 Glioblastoma Multiforme Market Overview at a Glance<\/p>\n<p style=\"text-align: justify;\">2.1 Market Share (%) Distribution of GBM in 2017<\/p>\n<p style=\"text-align: justify;\">2.2 Market Share (%) Distribution of GBM in 2030<\/p>\n<p style=\"text-align: justify;\">3 Executive Summary of Glioblastoma Multiforme (GBM)<\/p>\n<p style=\"text-align: justify;\">4 Disease Background and Overview: Glioblastoma Multiforme (GBM)<\/p>\n<p style=\"text-align: justify;\">5 Epidemiology and Patient Population<\/p>\n<p style=\"text-align: justify;\">6 Country Wise-Epidemiology of Glioblastoma Multiforme<\/p>\n<p style=\"text-align: justify;\">7 Treatment<\/p>\n<p style=\"text-align: justify;\">8 Treatment Algorithm<\/p>\n<p style=\"text-align: justify;\">9 The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma<\/p>\n<p style=\"text-align: justify;\">10 The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma<\/p>\n<p style=\"text-align: justify;\">11 Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions<\/p>\n<p style=\"text-align: justify;\">12 SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma<\/p>\n<p style=\"text-align: justify;\">13 Recognized Establishments<\/p>\n<p style=\"text-align: justify;\">14 Unmet Needs<\/p>\n<p style=\"text-align: justify;\">15 Marketed Drugs<\/p>\n<p style=\"text-align: justify;\">16 Emerging Drugs<\/p>\n<p style=\"text-align: justify;\">17 Glioblastoma Multiforme: 7 Major Market Analysis<\/p>\n<p style=\"text-align: justify;\">18 Market Access and Reimbursement<\/p>\n<p style=\"text-align: justify;\">19 Case Reports<\/p>\n<p style=\"text-align: justify;\">20 KOL Reviews<\/p>\n<p style=\"text-align: justify;\">21 Market Drivers<\/p>\n<p style=\"text-align: justify;\">22 Market Barriers<\/p>\n<p style=\"text-align: justify;\">23 SWOT Analysis<\/p>\n<p style=\"text-align: justify;\">24 Appendix<\/p>\n<p style=\"text-align: justify;\">25 DelveInsight Capabilities<\/p>\n<p style=\"text-align: justify;\">26 Disclaimer<\/p>\n<p style=\"text-align: justify;\">27 About DelveInsight<\/p>\n<p style=\"text-align: justify;\"><strong>Request for Detailed TOC @ https:\/\/www.delveinsight.com\/sample-request\/glioblastoma-multiforme-gbm-market<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>&nbsp;<\/strong><\/p>\n<p style=\"text-align: justify;\"><strong>About&nbsp;DelveInsight<\/strong><br \/> DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end-to-end comprehensive solutions to improve their performance.<\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/companyname\/delveinsight.com_57049.html\" rel=\"nofollow\">DelveInsight Business Research LLP<\/a><br \/><strong>Contact Person:<\/strong> Ankit Nigam<br \/><strong>Email:<\/strong> <a href=\"https:\/\/www.abnewswire.com\/email_contact_us.php?pr=glioblastoma-multiforme-market-industry-trends-drugs-therapies-and-analysis-by-delveinsight-genentech-merck-vbl-therapeutics-diffusion-pharmaceuticals-bayer-medimmune-dnatrix-oncoceutics\" rel=\"nofollow\">Send Email<\/a><br \/><strong>Phone:<\/strong> 9193216187<br \/><strong>Address:<\/strong>304 S. Jones Blvd #2432  <br \/><strong>City:<\/strong> Albany<br \/><strong>State:<\/strong> New York<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market\" target=\"_blank\" rel=\"nofollow\">https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market<\/a><\/p>\n<p><object type=\"text\/html\" data=\"https:\/\/www.delveinsight.com\/report-store\/glioblastoma-multiforme-gbm-market\" style=\"width:900px; height:400px;\"><\/object><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=glioblastoma-multiforme-market-industry-trends-drugs-therapies-and-analysis-by-delveinsight-genentech-merck-vbl-therapeutics-diffusion-pharmaceuticals-bayer-medimmune-dnatrix-oncoceutics\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Glioblastoma Multiforme Market Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/glioblastoma-multiforme-market-industry-trends-drugs-therapies-and-analysis-by-delveinsight-genentech-merck-vbl-therapeutics-diffusion-pharmaceuticals-bayer-medimmune-dnatrix-oncoceutics_539740.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401,405,417,406,423],"tags":[],"class_list":["post-539740","post","type-post","status-publish","format-standard","hentry","category-Business","category-Health-Medicine","category-Marketing-Sales","category-Pharmaceuticals-Biotech","category-Professional-Services"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539740","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=539740"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/539740\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=539740"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=539740"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=539740"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}